Off-the-Shelf CAR-T cells take on tough leukemia in early trial
NCT ID NCT07470073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new "universal" CAR-T cell therapy (CT1190B) for people aged 12-75 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The therapy is made from donor cells, so it can be given without needing the patient's own cells. The main goals are to check safety, find the best dose, and see how well it works at shrinking the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cheaper copy of a leukemia drug work just as well?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Combination therapy aims to keep leukemia in check after transplant
- Engineered immune cells take aim at tough childhood cancers
- Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse